PLLA Dermal Filler: Injection Techniques, Patient Selections, and Safety Considerations

Advances in AML: The Role of a BCL-2 Inhibitor in Current Treatment Paradigms

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS

With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.

The Ramp-Up & Dosing of an Acute Myeloid Leukemia Therapy

Guest: Ilene Galinsky BSN,MSN,ANP-C

Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.

Osteoporosis Update: Keys to Improving Diagnosis & Preventing Fractures

Host: Matt Birnholz, MD
Guest: Susan Greenspan, MD
Guest: John Carey, MB, BCh, BAO

It is estimated that 54 million Americans over the age of 50 are affected by osteoporosis and low-density bone mass, putting them at higher risk for fractures. Additionally, new evidence is emerging that the 30-year downward trend in hip fractures has hit a plateau recently, indicating that the field, as a whole, must take action to aggressively reduce this danger in our aging population.

Dr. John Carey, President of the International Society for Clinical Densitometry, and Dr. Susan Greenspan, Vice President of the National Osteoporosis Foundation, speak with host Dr. Matt Birnholz about diagnostic and treatment priorities for osteoporosis to help reduce fractures.

PLLA Dermal Filler: Injection Techniques, Patient Selections, and Safety Considerations

Dr. Becky Fitzgerald, a dermatologist in private practice in Los Angeles, CA and on the clinical faculty at UCLA, and Dr. Sabrina Fabi, dermatologist, assistant clinical professor at the University of California, San Diego, and associate at Cosmetic Laser Dermatology, discuss Poly-L-lactid Acid (PLLA) injections and how to best employ this unique product cosmetically for patients.

The Problem of Drug Diversion in Healthcare Settings

Drug diversion is the illegal distribution or abuse of prescription drugs or their use for unintended purposes. The diversion of prescription drugs may occur at any point as prescription drugs are distributed from the manufacturer to wholesale distributors, to pharmacies, and ultimately to the patient. Though this problem is nearly universal among healthcare instititions, many don't have adequate processes in place to detect it. Moreover, concerns about civil and regulatory liability, as well as negative publicity, often impede healthcare organizations from reporting instances of drug diversion.

Dr. Howard Zucker, New York State Department of Health Commissioner, speaks with noted provider drug diversion expert Kimberly New, JD, BSN, RN about how prevalent the problem of drug diversion is, the signs of potential drug diversion activity, and how to set up a robust facility program to avert potential diversion events.

This program is provided on behalf of the New York One and Only Campaign, a public health effort led by the Centers for Disease Control and Prevention (CDC) and the Safe Injection Practices Coalition (SIPC) to raise awareness among patients and healthcare providers about safe injection practices.